Cargando…
A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy
INTRODUCTION: Image guidance with gold fiducials improves outcomes of prostate radiotherapy. However, gold produces artefact on CT imaging, interfering with contouring and verification. The purpose of this study was to compare polymer to standard gold fiducials using radiotherapy imaging modalities...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930895/ https://www.ncbi.nlm.nih.gov/pubmed/36818674 http://dx.doi.org/10.3389/fonc.2022.1023288 |
_version_ | 1784889128061501440 |
---|---|
author | Lim Joon, Daryl Berry, Colleen Harris, Benjamin Tacey, Mark Smith, Drew Lawrentschuk, Nathan Schneider, Michal Elisabeth Fraser, Olivia Hall, Megan Chao, Michael Foroudi, Farshad Jenkins, Trish Angus, David Wada, Morikatsu Sengupta, Shomik Khoo, Vincent |
author_facet | Lim Joon, Daryl Berry, Colleen Harris, Benjamin Tacey, Mark Smith, Drew Lawrentschuk, Nathan Schneider, Michal Elisabeth Fraser, Olivia Hall, Megan Chao, Michael Foroudi, Farshad Jenkins, Trish Angus, David Wada, Morikatsu Sengupta, Shomik Khoo, Vincent |
author_sort | Lim Joon, Daryl |
collection | PubMed |
description | INTRODUCTION: Image guidance with gold fiducials improves outcomes of prostate radiotherapy. However, gold produces artefact on CT imaging, interfering with contouring and verification. The purpose of this study was to compare polymer to standard gold fiducials using radiotherapy imaging modalities to assess the visibility and artefact. METHODS: Twenty eight patients with locally advanced prostate cancer were enrolled, half had three polymer fiducials implanted into the prostate and half underwent insertion of gold fiducials. Patients were imaged with CT, T2 weighted MRI, cone-beam CT (CBCT) and planar KV images. Fiducials were scored for visibility and assessed for CT artefact in surrounding prostate tissue. The artefact was quantified from Hounsfield number histograms and separated into percentile ranges and proportion of voxels in HU normal tissue range of a 2cm sphere surrounding the fiducial. RESULTS: Gold and polymer fiducials were sufficiently visible for CT and CBCT verification. The gold fiducials could be visualized well on KV planar imaging; however, the polymer markers were obscured by pelvic bones. Neither polymer nor gold fiducials could be visualized on MRI. The polymer fiducial produced less artefact than gold on CT, having less voxel spread for the HU percentile ranges and a greater proportion of voxels in the normal tissue range. CONCLUSIONS: Polymer fiducials are a more suitable fiducial than gold for CT/CBCT in prostate cancer radiotherapy, demonstrating minimal artefact and good visibility on CT. However, they were not well seen on MRI or KV imaging and thus not suitable for co-registration or planar KV verification. |
format | Online Article Text |
id | pubmed-9930895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99308952023-02-16 A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy Lim Joon, Daryl Berry, Colleen Harris, Benjamin Tacey, Mark Smith, Drew Lawrentschuk, Nathan Schneider, Michal Elisabeth Fraser, Olivia Hall, Megan Chao, Michael Foroudi, Farshad Jenkins, Trish Angus, David Wada, Morikatsu Sengupta, Shomik Khoo, Vincent Front Oncol Oncology INTRODUCTION: Image guidance with gold fiducials improves outcomes of prostate radiotherapy. However, gold produces artefact on CT imaging, interfering with contouring and verification. The purpose of this study was to compare polymer to standard gold fiducials using radiotherapy imaging modalities to assess the visibility and artefact. METHODS: Twenty eight patients with locally advanced prostate cancer were enrolled, half had three polymer fiducials implanted into the prostate and half underwent insertion of gold fiducials. Patients were imaged with CT, T2 weighted MRI, cone-beam CT (CBCT) and planar KV images. Fiducials were scored for visibility and assessed for CT artefact in surrounding prostate tissue. The artefact was quantified from Hounsfield number histograms and separated into percentile ranges and proportion of voxels in HU normal tissue range of a 2cm sphere surrounding the fiducial. RESULTS: Gold and polymer fiducials were sufficiently visible for CT and CBCT verification. The gold fiducials could be visualized well on KV planar imaging; however, the polymer markers were obscured by pelvic bones. Neither polymer nor gold fiducials could be visualized on MRI. The polymer fiducial produced less artefact than gold on CT, having less voxel spread for the HU percentile ranges and a greater proportion of voxels in the normal tissue range. CONCLUSIONS: Polymer fiducials are a more suitable fiducial than gold for CT/CBCT in prostate cancer radiotherapy, demonstrating minimal artefact and good visibility on CT. However, they were not well seen on MRI or KV imaging and thus not suitable for co-registration or planar KV verification. Frontiers Media S.A. 2023-02-01 /pmc/articles/PMC9930895/ /pubmed/36818674 http://dx.doi.org/10.3389/fonc.2022.1023288 Text en Copyright © 2023 Lim Joon, Berry, Harris, Tacey, Smith, Lawrentschuk, Schneider, Fraser, Hall, Chao, Foroudi, Jenkins, Angus, Wada, Sengupta and Khoo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Lim Joon, Daryl Berry, Colleen Harris, Benjamin Tacey, Mark Smith, Drew Lawrentschuk, Nathan Schneider, Michal Elisabeth Fraser, Olivia Hall, Megan Chao, Michael Foroudi, Farshad Jenkins, Trish Angus, David Wada, Morikatsu Sengupta, Shomik Khoo, Vincent A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy |
title | A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy |
title_full | A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy |
title_fullStr | A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy |
title_full_unstemmed | A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy |
title_short | A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy |
title_sort | clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930895/ https://www.ncbi.nlm.nih.gov/pubmed/36818674 http://dx.doi.org/10.3389/fonc.2022.1023288 |
work_keys_str_mv | AT limjoondaryl aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT berrycolleen aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT harrisbenjamin aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT taceymark aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT smithdrew aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT lawrentschuknathan aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT schneidermichalelisabeth aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT fraserolivia aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT hallmegan aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT chaomichael aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT foroudifarshad aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT jenkinstrish aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT angusdavid aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT wadamorikatsu aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT senguptashomik aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT khoovincent aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT limjoondaryl clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT berrycolleen clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT harrisbenjamin clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT taceymark clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT smithdrew clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT lawrentschuknathan clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT schneidermichalelisabeth clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT fraserolivia clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT hallmegan clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT chaomichael clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT foroudifarshad clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT jenkinstrish clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT angusdavid clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT wadamorikatsu clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT senguptashomik clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy AT khoovincent clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy |